Eduovisual
Pregnancy, Childbirth & Puerperium
Multiple gestation: management
— Dichorionic-diamniotic (DCDA): 2 placentas, 2 sacs — all dizygotic + ~30% of monozygotic
— Monochorionic-diamniotic (MCDA): shared placenta, 2 sacs — splits day 4–8 — risk of TTTS/TAPS/sIUGR
— Monochorionic-monoamniotic (MCMA): shared sac — splits day 8–13 — cord entanglement, ~10–15% mortality
— Conjoined: split >day 13
— Uterine size > dates by ≥3–4 cm
— Two distinct fetal heart tones on Doppler
— Hyperemesis disproportionate to singleton norms
— Markedly elevated β-hCG, MSAFP, or abnormal cell-free DNA screen
— History of ART, family history of dizygotic twins, maternal age >35
— Lambda (twin-peak) sign → dichorionic
— T-sign (thin perpendicular membrane) → monochorionic diamniotic
— Absent inter-twin membrane → monoamniotic
Board pearl: Chorionicity must be documented before 14 weeks; after that, the lambda/T-sign distinction becomes unreliable and management decisions (surveillance frequency, delivery timing, TTTS risk) hinge on a less certain call. If a patient presents at 22 weeks without documented chorionicity, treat as monochorionic until proven otherwise.
Step 3 management: A positive home pregnancy test with size-greater-than-dates exam → order transvaginal ultrasound before 14 weeks, not just routine 20-week anatomy scan.
— Severe hyperemesis gravidarum (high hCG load)
— Early or exaggerated symptoms: breast tenderness, fatigue, urinary frequency
— Quantitative β-hCG higher than expected for gestational age (nonspecific but suggestive)
— Abnormal serum screening: elevated MSAFP, low PAPP-A patterns, or "no-call"/inconclusive cell-free DNA
— Fundal height >3 cm greater than expected
— Multiple sets of fetal heart tones
— Excessive maternal weight gain
— Earlier and more pronounced lower extremity edema, varicosities, hemorrhoids, dyspnea
— Worsening anemia despite iron supplementation (expanded plasma volume + 2 fetuses drawing iron)
— Method of conception: spontaneous vs ovulation induction (clomiphene/letrozole) vs IVF (number of embryos transferred)
— Family history of twins (maternal side for dizygotic predisposition)
— Prior pregnancy outcomes, especially preterm birth or cervical insufficiency
— Prior cesarean (affects mode of delivery planning)
— Maternal age, BMI, chronic HTN, pregestational DM, thyroid disease, thrombophilia
— Medications, including teratogens and any ART-related hormonal therapy
— Sudden abdominal distension/pain in MCDA → suspect twin-twin transfusion syndrome (TTTS) with polyhydramnios in recipient
— Decreased fetal movement (especially in monoamniotic — cord accident)
— Vaginal bleeding (abruption, previa — both more common in twins)
— Persistent headache, RUQ pain, visual changes → preeclampsia, often earlier and more severe
Key distinction: Hyperemesis + size>dates + bilateral theca lutein cysts can mimic molar pregnancy; ultrasound distinguishes immediately. Don't anchor on molar without imaging — multiples are far more common, especially post-ART.
Board pearl: A "no-call" cell-free DNA result should prompt repeat draw AND ultrasound — multiple gestation is a leading cause of failed cfDNA due to fetal fraction dilution. Counsel that screening accuracy is reduced in twins; diagnostic CVS/amniocentesis remains the gold standard when indicated.
— Disproportionately gravid abdomen for gestational age
— Exaggerated lordosis, peripheral edema, pallor (dilutional anemia)
— Possible signs of volume overload: JVD, bibasilar crackles in late pregnancy or with preeclampsia
— Plasma volume expansion is 50–100% above nonpregnant, vs ~40% in singletons → greater cardiac output demand
— Resting tachycardia (HR 90–110) is common
— BP trends: mid-pregnancy nadir may be blunted; rising BP in 2nd trimester is a red flag for early preeclampsia
— Orthostatic symptoms from IVC compression occur earlier (~20 weeks)
— Fundal height: measure but interpret cautiously — typically exceeds GA in cm by ≥4
— Leopold maneuvers: palpate ≥3 fetal poles; presentation of presenting twin guides delivery planning
— Fetal heart tones: auscultate two distinct rates differing by ≥10 bpm in different locations
— Cervical exam: assess for shortening or dilation; consider transvaginal cervical length at 18–24 weeks
— Cardiac: physiologic S3, soft systolic flow murmurs are normal; a diastolic murmur or S4 is pathologic
— Pulmonary: dyspnea is common from diaphragmatic elevation, but hypoxia is not — pulse ox <95% warrants workup (PE, pulmonary edema)
— Extremities: asymmetric leg swelling/calf tenderness → evaluate for DVT (multiples increase VTE risk further over baseline pregnancy)
— Skin/neuro: brisk reflexes, clonus, RUQ tenderness → preeclampsia spectrum
CCS pearl: On a CCS case with twin pregnancy at 32 weeks presenting with headache and BP 152/98 — order CBC, CMP, LDH, uric acid, urine protein/creatinine, fetal NST, biophysical profile, and continuous fetal monitoring in that visit. Don't forget magnesium sulfate if severe features emerge and betamethasone if delivery within 7 days is anticipated and last course was >14 days ago.
Board pearl: Always identify presenting twin (Twin A) position — if Twin A is non-vertex, cesarean is standard regardless of Twin B presentation.
— Confirms viability, number of fetuses, chorionicity, and amnionicity
— Crown-rump length of the larger twin sets the EDD (ACOG)
— Nuchal translucency for each fetus
— Document number of placentas, membrane thickness, lambda vs T-sign
— CBC: anemia threshold Hgb <11 g/dL (1st/3rd trimester), <10.5 g/dL (2nd trimester) — iron stores depleted faster
— Blood type, Rh, antibody screen
— Rubella, varicella, HIV, hepatitis B/C, syphilis (RPR), gonorrhea/chlamydia, urine culture
— TSH if symptomatic or risk factors
— Hemoglobin A1c if risk factors for pregestational DM
— cfDNA can be used in twins but has lower sensitivity and higher no-call rate; counsel limitations
— First-trimester combined screening (NT + PAPP-A + hCG) acceptable; interpret per-fetus
— Quad screen less accurate in twins
— Diagnostic testing: CVS or amniocentesis — both fetuses must be sampled separately; mapping is critical
— Standard 1-hour 50-g GCT at 24–28 weeks; some centers screen earlier given higher GDM risk
— Detailed survey at 18–22 weeks for each fetus; document growth, anatomy, cervical length
Step 3 management: Order a transvaginal cervical length at the anatomy scan in all twin pregnancies. Length <25 mm before 24 weeks identifies the cohort at highest risk for preterm birth, though cerclage is generally not indicated for short cervix in twins alone (unlike singletons) — except for history-indicated cases. Vaginal progesterone may reduce PTB in twins with short cervix (evolving data; ACOG considers it reasonable).
Board pearl: MSAFP is roughly 2× the singleton median in twins — don't misinterpret as neural tube defect without correlating to ultrasound and gestation count.
— DCDA: growth scan every 4 weeks starting at 24–28 weeks
— MCDA: ultrasound every 2 weeks from 16 weeks through delivery to screen for TTTS/TAPS/sIUGR
— MCMA: every 2 weeks from 16 weeks; many centers hospitalize at 24–28 weeks for daily monitoring
— Assess deepest vertical pocket (DVP) in each sac
— Polyhydramnios in one sac (DVP >8 cm) + oligohydramnios in the other (DVP <2 cm) = TTTS by Quintero staging
— Stage I: oligo/poly only; Stage II: absent bladder in donor; Stage III: abnormal Dopplers (UA, DV, UV); Stage IV: hydrops; Stage V: demise
— Discordant middle cerebral artery peak systolic velocity (MCA-PSV): donor >1.5 MoM, recipient <1.0 MoM, without oligo/polyhydramnios
— Estimated fetal weight discordance ≥20–25% or one twin <10th percentile
— Begin NST or BPP at 32 weeks for uncomplicated DCDA, earlier (24–28 weeks) for MC twins or growth-restricted/discordant
— Frequency typically weekly to twice weekly depending on risk
— Umbilical artery Doppler for growth-restricted or discordant twins
— Ductus venosus and MCA-PSV in monochorionic complications
— Recommended for all monochorionic pregnancies (higher cardiac anomaly rate) and any with TTTS
Key distinction: TTTS = amniotic fluid discordance; TAPS = hemoglobin discordance without fluid discordance; sIUGR = weight discordance. They overlap but require distinct surveillance and intervention thresholds.
Board pearl: New polyhydramnios in one sac of MCDA twins at 18–26 weeks demands urgent referral to a fetal therapy center — fetoscopic laser photocoagulation of placental anastomoses is the treatment of choice for Quintero stage II+ TTTS before 26 weeks.
— DCDA: lowest-risk multiple gestation; standard prenatal care intensified
— MCDA: TTTS/TAPS/sIUGR risk; biweekly US from 16 weeks
— MCMA: cord entanglement → inpatient monitoring late 2nd/early 3rd trimester at many centers
— Maternal: age >35, chronic HTN, pregestational DM, prior PTB, BMI extremes
— Pregnancy-related: short cervix, GDM, preeclampsia, abnormal placentation
— Fetal: anomalies, growth discordance, abnormal Dopplers
— DCDA: 38 0/7 weeks
— MCDA: 36 0/7–37 6/7 weeks
— MCMA: 32 0/7–34 0/7 weeks (with antenatal corticosteroids)
— Complicated (TTTS post-laser, sIUGR, discordance, preeclampsia, GDM on meds): individualize, often 34–37 weeks
— Vertex/vertex (~40%): vaginal delivery attempt appropriate
— Vertex/non-vertex (~35%): vaginal delivery of Twin A; Twin B via breech extraction or external cephalic version, by experienced provider, if EFW 1500–4000 g and concordant
— Non-vertex Twin A: cesarean delivery
— MCMA: cesarean standard (cord entanglement risk during labor)
— Low-dose aspirin 81 mg daily starting 12–16 weeks (multiple gestation is itself a moderate risk factor — combined with any other moderate factor or 1 high risk factor = indicated)
— No evidence routine bed rest improves outcomes; can worsen VTE risk
— Caloric needs ~+300 kcal/fetus; iron, folate, calcium supplementation
Step 3 management: For a 32-year-old with DCDA twins, no other risk factors, at 12 weeks → start ASA 81 mg, prenatal vitamin with iron, schedule anatomy scan with cervical length, plan growth scans q4 weeks from 24 weeks, target delivery 38 0/7 weeks.
— 81 mg PO daily, initiated 12–16 weeks, continued until delivery
— Multiple gestation alone is a moderate USPSTF/ACOG risk factor; combine with any other moderate or one high-risk factor for indication
— Elemental iron 30–60 mg/day; increase to 60–100 mg/day if iron-deficiency anemia
— Folic acid 0.4–0.8 mg/day (4 mg if prior NTD or on antiepileptics)
— Calcium 1000 mg, vitamin D 600 IU minimum
— Betamethasone 12 mg IM × 2 doses 24 h apart (or dexamethasone) when delivery anticipated within 7 days between 24 0/7 and 33 6/7 weeks
— Late preterm rescue course (34 0/7–36 6/7 weeks) if not previously given and delivery imminent
— Single rescue course if >14 days since first and <34 weeks
— Neuroprotection if delivery imminent <32 weeks
— Seizure prophylaxis in preeclampsia with severe features or eclampsia: 4–6 g IV load, then 1–2 g/hr
— Short-term (≤48 h) to permit ACS administration and transfer; nifedipine or indomethacin (<32 weeks)
— Avoid prolonged tocolysis; terbutaline carries black-box warning for cardiac events beyond 48–72 h
— Vaginal progesterone may reduce PTB in twin pregnancies with short cervix (<25 mm); routine progesterone in unselected twins is not beneficial
— Mechanical prophylaxis during cesarean
— Pharmacologic LMWH if additional risk factors (prior VTE, thrombophilia, prolonged immobility)
Board pearl: Cervical cerclage in twins has not been shown to reduce PTB in unselected populations and may increase risk — reserve for history-indicated cases or cervical dilation on exam in select referral settings.
Step 3 management: Twin pregnancy at 30 weeks with PPROM → admit, betamethasone, latency antibiotics (ampicillin + azithromycin → amoxicillin), magnesium for neuroprotection if delivery <32 weeks, fetal monitoring, plan delivery at 34 weeks unless infection/distress.
— Treatment of choice for Quintero stage II–IV TTTS before 26 weeks
— Selectively coagulates inter-twin placental anastomoses
— Improves dual-survival rates compared with serial amnioreduction or expectant management
— Performed at specialized fetal therapy centers
— Used in late-presenting TTTS (>26 weeks) or as adjunct; relieves maternal symptoms and may prolong pregnancy
— Multifetal pregnancy reduction (MFPR): in higher-order multiples (triplets, quadruplets) to reduce PTB and improve outcomes; typically performed 11–14 weeks
— Selective termination: for severe discordant anomaly; in monochorionic pregnancies, requires cord occlusion (radiofrequency ablation, bipolar) because shared circulation precludes KCl injection (would kill co-twin)
— Limited role; consider history-indicated or physical-exam-indicated in select referral cases
— Cesarean indications: MCMA, non-vertex Twin A, ≥3 fetuses, Twin B EFW >20% larger than A in vertex/non-vertex pair, prior classical cesarean
— Vaginal twin delivery requirements: experienced operator, continuous EFM of both fetuses, dual IV access, blood available, anesthesia immediately available, OR ready for emergent cesarean
— Between deliveries of Twin A and Twin B: confirm presentation by intrapartum ultrasound, monitor Twin B continuously; deliver as vertex, breech extraction, or ECV based on lie
— Postpartum: active management of third stage — high PPH risk from overdistended uterus → oxytocin infusion, have methylergonovine, carboprost, tranexamic acid, misoprostol available
CCS pearl: After delivery of twins, immediately order oxytocin 20–40 U in 1 L NS at 200–500 mL/hr, assess fundal tone every 15 minutes for the first hour, type and screen current, and monitor quantitative blood loss. Uterine atony is the leading cause of PPH in multiples.
Board pearl: Selective termination in monochorionic twins is never KCl injection — shared anastomoses mean drug crosses to co-twin.
— Higher background risk of chronic HTN, type 2 DM, aneuploidy, placenta previa/accreta, cesarean delivery
— Multiple gestation compounds preeclampsia and GDM risk; aspirin prophylaxis essentially universal
— Counsel on age-related aneuploidy risk per fetus — twin pregnancy with one Down syndrome fetus has different counseling implications than singleton
— Offer diagnostic testing (CVS/amnio) discussion early; reduction options if higher-order
— Target BP <140/90 in pregnancy; first-line agents labetalol, nifedipine XR, methyldopa
— Avoid ACEi/ARBs (teratogenic, fetal renal failure 2nd/3rd trimester)
— Monitor for superimposed preeclampsia — common and earlier in twins
— Tight glycemic control, fasting <95, 1-hr postprandial <140
— Insulin preferred; metformin/glyburide cross placenta and have evolving data
— Higher risk of congenital anomalies — detailed anatomy scan + fetal echo
— Pre-pregnancy Cr >1.4 mg/dL: counsel on progression risk
— Monitor proteinuria; distinguish baseline from new preeclampsia (look at uric acid, LDH, platelets, AST/ALT rather than proteinuria alone)
— Watch for HELLP, acute fatty liver of pregnancy (AFLP), intrahepatic cholestasis — all more common in multiples
— AFLP: hypoglycemia, coagulopathy, encephalopathy — delivery is treatment
— ICP: pruritus + elevated bile acids → ursodeoxycholic acid, deliver 36–37 weeks (earlier if bile acids ≥100)
— Twin physiology imposes higher CO demand; high-risk lesions (severe MS, pulmonary HTN, Eisenmenger, dilated cardiomyopathy EF <30%) — multidisciplinary planning, often early delivery
Step 3 management: A 41-year-old G1 with DCDA twins and chronic HTN at 10 weeks → switch lisinopril to labetalol, start ASA 81 mg at 12 weeks, baseline labs (Cr, urine protein/Cr, EKG), MFM referral, anatomy + fetal echo, plan delivery 37–38 weeks pending stability.
Board pearl: New-onset HTN before 20 weeks in twins is more often chronic HTN unmasked or molar; preeclampsia before 20 weeks is rare and prompts molar/antiphospholipid workup.
— Higher risk of PTB, preeclampsia, anemia, social vulnerability
— Confidentiality nuances per state law; engage parents/guardians supportively
— Connect to social work, WIC, home visiting programs early
— Higher rate of monozygotic twinning even after single embryo transfer (~2× background)
— Increased risk of placenta previa, vasa previa, velamentous cord insertion — perform careful placental and cord evaluation at anatomy scan; consider transvaginal US for previa/vasa previa if risk factors
— Counsel pre-conception on single embryo transfer to minimize multiples
— Vastly higher PTB, IUGR, preeclampsia, GDM, mortality
— Multifetal pregnancy reduction (MFPR) discussion at 11–14 weeks; reducing triplets to twins generally improves overall outcomes
— Delivery typically cesarean at 35–36 weeks (triplets); MCMA components push earlier
— MFM co-management, anesthesia consult, NICU readiness
— Compounded GDM, preeclampsia, VTE, shoulder dystocia (less relevant in PTB), wound complications post-cesarean
— Anesthesia consultation antenatally; consider early epidural placement
— One twin lost in 1st trimester; if confirmed before 14 weeks, outcome for surviving twin generally good
— Loss after 14 weeks (especially in MC): risk of neurologic injury or demise of co-twin from acute hemodynamic shift via anastomoses — urgent MFM evaluation
— ~15% risk of co-twin death; ~25% neurologic injury risk in survivor
— MRI of survivor at 4–6 weeks post-event; expectant management often preferred over immediate delivery
Key distinction: Demise of one twin in dichorionic pregnancy generally does not endanger the survivor (no shared circulation); in monochorionic, it can cause acute exsanguination via anastomoses — surveillance approach differs entirely.
Board pearl: ART increases monozygotic twinning — chorionicity assessment is still mandatory even after single embryo transfer.
— ~60% of twins deliver <37 weeks; ~12% <32 weeks
— Spontaneous and indicated (preeclampsia, growth restriction)
— Major driver of neonatal morbidity/mortality
— 2–3× singleton risk; often earlier and more severe
— Atypical presentations (HELLP without HTN) more common
— ~2× singleton risk; screen at 24–28 weeks; treat with diet, then insulin/metformin
— Iron deficiency very common; check Hgb at intake, 24–28 weeks, and predelivery
— Uterine overdistension → atony; have uterotonics + TXA ready
— Pregnancy increases risk 4–5×; multiples and cesarean further elevate
— Discussed in chunks 5 and 8
— MC pregnancies: surviving twin neurologic injury risk
— MCMA: cord entanglement → fetal demise
— Velamentous insertion, vasa previa → fetal exsanguination at ROM
— Higher cesarean rate; if vaginal, second twin delivery complications (cord prolapse, abruption after first delivery)
— Increased baseline; large placental footprint
— Pulmonary edema (especially with magnesium + tocolytics + IVF), peripartum cardiomyopathy risk slightly elevated
— Lower birth weight, NICU admission, RDS, IVH, NEC, long-term neurodevelopmental impact in extremes of prematurity
— Cerebral palsy risk 4× singleton (driven mainly by prematurity)
CCS pearl: Twin gestation postpartum with brisk vaginal bleeding and boggy fundus → fundal massage, oxytocin already running, methylergonovine 0.2 mg IM (avoid if HTN), carboprost 250 mcg IM (avoid in asthma), TXA 1 g IV, bimanual compression, call for help, type and crossmatch, consider intrauterine balloon, escalate to OR for B-Lynch / hysterectomy if refractory.
Board pearl: Vasa previa → planned cesarean at 34–35 6/7 weeks after antenatal corticosteroids; ruptured membranes with painless bleeding + fetal bradycardia in known/unknown vasa previa is an obstetric emergency.
— All monochorionic pregnancies (at minimum co-management)
— Higher-order multiples
— TTTS/TAPS/sIUGR or discordant growth
— Major fetal anomaly
— Maternal chronic disease: pregestational DM, chronic HTN, autoimmune, cardiac, renal disease
— Prior PTB, cervical insufficiency, short cervix
— TTTS Quintero stage II+ before 26 weeks → fetoscopic laser
— Severe sIUGR or TAPS requiring intervention
— Suspected vasa previa/placenta accreta spectrum
— Preterm labor, PPROM
— Preeclampsia with severe features
— Significant antepartum bleeding
— MCMA pregnancy at 24–28 weeks per institutional protocol
— Acute fatty liver of pregnancy, HELLP
— Eclampsia
— Pulmonary edema requiring ventilation, ARDS
— Massive hemorrhage with hemodynamic instability
— DIC, AFLP
— Amniotic fluid embolism
— Stroke, status epilepticus
— Severe cardiac decompensation
— Early in pregnancy for obesity, difficult airway, cardiac disease, coagulopathy
— Plan epidural early in labor — facilitates rapid conversion to cesarean for Twin B emergencies
— Notify NICU before delivery; ensure adequate warmers and personnel — one team per fetus
— Periviable delivery (22–25 weeks): involve neonatology for shared decision-making about resuscitation
Step 3 management: Twin pregnancy at 25 weeks at a community hospital with new-onset polyhydramnios in one sac of MCDA twins → call MFM, arrange maternal transport to fetal therapy center, antenatal steroids if delivery becomes imminent, do not delay transfer for full workup at sending hospital.
CCS pearl: Always order "obstetrics consult" and "neonatology consult" early in twin delivery cases; the clock advances and these are time-sensitive.
— Multiple gestation (this topic)
— Inaccurate dating — most common cause; reassess by first-trimester CRL
— Polyhydramnios (singleton):
— Maternal: pregestational/gestational diabetes
— Fetal: anomalies (esophageal/duodenal atresia, neural tube defects, anencephaly), infection (CMV, parvovirus, syphilis, toxoplasmosis), hydrops, chromosomal
— Macrosomia: maternal DM, post-dates, constitutional
— Uterine fibroids: enlarge with pregnancy; tender if degenerating
— Gestational trophoblastic disease (molar pregnancy):
— Hyperemesis, size>dates, abnormally high β-hCG, theca lutein cysts, "snowstorm" or "cluster-of-grapes" on US
— Complete mole: 46,XX, no fetus; partial mole: triploid with fetal parts
— Ovarian mass: corpus luteum cyst, theca lutein cysts, neoplasm
— Maternal obesity / bladder distension: falsely elevates fundal height measurement
— DCDA vs MCDA vs MCMA — by chorionicity findings on early US
— TTTS vs TAPS vs sIUGR — by amniotic fluid, MCA-PSV, and growth metrics
— Concordant vs discordant twins — ≥20% EFW difference is significant
— True knot vs cord entanglement (MCMA) vs nuchal cord — sonographic and Doppler features differ
— Triplets, quadruplets, quintuplets — confirm chorionicity for each fetus; combinations of mono/dichorionic possible
Key distinction: Molar pregnancy and twin pregnancy can both present with size>dates and hyperemesis with elevated β-hCG; only ultrasound differentiates. A complete mole with coexistent normal twin is rare but possible — exists in ~1 in 22,000–100,000 pregnancies and requires MFM/oncology co-management.
Board pearl: Discordance ≥20% in twins requires growth scan follow-up every 2 weeks and Doppler surveillance; ≥25% raises consideration for early delivery between 34–36 weeks depending on fetal status.
— Ovarian neoplasm with concurrent pregnancy
— Large leiomyomata with degeneration
— Hydrosalpinx or tubo-ovarian abscess
— Ascites from heart failure, cirrhosis, malignancy (Meigs syndrome)
— Gestational trophoblastic disease
— Misdated singleton pregnancy
— Aneuploidy (e.g., trisomy 21 has higher hCG)
— hCG-secreting tumors (germ cell, choriocarcinoma)
— Multiples, molar pregnancy
— Hyperthyroidism (β-hCG cross-reacts at TSH receptor)
— Gastroenteritis, biliary disease, pyelonephritis, hepatitis, pancreatitis
— Increased ICP (rare): consider if focal neuro signs
— Pulmonary embolism — sudden, hypoxia, tachycardia, asymmetric leg swelling
— Pulmonary edema (preeclampsia, peripartum cardiomyopathy, iatrogenic fluid overload)
— Asthma exacerbation
— Pneumonia/COVID
— Amniotic fluid embolism (peripartum, sudden collapse + DIC)
— Chronic HTN with superimposed proteinuria from underlying renal disease
— Lupus nephritis flare
— Pheochromocytoma (rare; paroxysmal HTN, headache, palpitations)
— TTP/HUS — schistocytes, severe thrombocytopenia, neuro signs, AKI; delivery does not resolve TTP; needs plasma exchange
— AFLP — hypoglycemia, ammonia elevation, profound coagulopathy
— Acute viral hepatitis
— TTP, HUS, antiphospholipid syndrome catastrophic
Key distinction: HELLP improves after delivery; TTP does not. Persistent or worsening thrombocytopenia and hemolysis 48–72 h post-delivery → suspect TTP/HUS → ADAMTS13, plasma exchange, hematology consult. Critical not to anchor on HELLP.
Board pearl: Dyspnea + hypoxia + clear lungs in third-trimester twin → PE until proven otherwise; CT pulmonary angiogram is safe and indicated when clinically warranted.
— Iron supplementation for ongoing anemia; check Hgb 4–6 weeks postpartum
— VTE prophylaxis after cesarean — mechanical and/or LMWH per risk score (cesarean + twins + obesity = higher risk)
— Continue antihypertensives if BP elevated; preeclampsia BP can persist or worsen for up to 2 weeks postpartum
— Magnesium sulfate for 24 hours postpartum if delivered for severe preeclampsia
— Reliable contraception especially important if breastfeeding twins (high demand) and recovery period
— LARC (IUD, implant) safe immediately postpartum; progestin-only methods preferred while breastfeeding in first 21 days due to VTE concern with combined estrogen
— Tubal ligation at time of cesarean if desired (require pre-procedure consent timing per institution)
— Optimize chronic conditions (HTN, DM, weight, thyroid)
— Encourage interpregnancy interval ≥18 months, especially after cesarean
— Counsel on recurrence risk of multiples (modestly increased after one twin pregnancy)
— Preeclampsia/GDM in pregnancy = lifelong elevated CVD risk; refer for primary care with attention to BP, lipids, glucose
— GDM patients: 75-g 2-hour OGTT at 4–12 weeks postpartum, then every 1–3 years; lifelong T2DM risk ~50%
— Higher rates of postpartum depression and anxiety in mothers of multiples — screen with EPDS at 2 and 6 weeks and ongoing
— Twins can breastfeed; lactation consultant referral; tandem feeding techniques
— Domperidone not FDA-approved; reglan has side effects
— Diastasis recti and pelvic floor dysfunction more common after twin pregnancy — PT referral
Step 3 management: Postpartum twin mom with preeclampsia, BP 152/96 at 1-week visit → continue/initiate nifedipine XR or labetalol, recheck BP in 3–7 days, review preeclampsia warning signs, schedule comprehensive 6-week visit, EPDS screen, CV risk counseling as part of long-term plan.
Board pearl: History of preeclampsia warrants annual BP and CV risk assessment — it is a female-specific CVD risk enhancer per ACC/AHA.
— Monthly through 24 weeks
— Every 2 weeks 24–32 weeks
— Weekly from 32 weeks
— MCDA: ultrasound every 2 weeks from 16 weeks
— MCMA: ultrasound every 2 weeks plus consideration of inpatient monitoring at 24–28 weeks
— Maternal BP, weight, urine dip (if symptomatic), fundal height (trended cautiously)
— Glucose log if GDM
— Fetal growth, fluid, Dopplers, BPP/NST per protocol
— Cervical length 18–24 weeks
— 1st: chorionicity, screening options (cfDNA limitations in twins, CVS/amnio), nutrition, ASA prophylaxis
— 2nd: PTB symptoms, preeclampsia signs, fetal movement awareness (often inconsistent between twins), GDM screening
— 3rd: delivery mode and timing, hospital plans, breastfeeding, anesthesia, postpartum support, NICU possibility
— Vaginal bleeding, rupture of membranes, regular contractions before 37 weeks
— Severe headache, visual changes, RUQ pain, sudden swelling
— Decreased fetal movement (despite difficulty distinguishing between twins, reduced overall activity warrants evaluation)
— Dyspnea, chest pain, calf swelling
— Early postpartum visit at 1–2 weeks for cesarean or preeclampsia patients
— Comprehensive 4–6 week visit for contraception, mood, BP, glucose (post-GDM)
— Pediatric follow-up coordinated, especially after NICU discharge
— Connect with Multiples of America / Twin Parent groups, social work for resources
Step 3 management: Twin pregnancy at 35 weeks with new BP 148/92, normal labs, no symptoms → diagnose gestational hypertension, twice-weekly BP checks, weekly labs, twice-weekly NST/BPP, plan delivery at 37 weeks (or sooner if severe features develop).
Board pearl: Decreased fetal movement in twin pregnancy is challenging — counsel mothers to report overall reduction rather than try to count each fetus separately; any concern warrants NST.
— Complex decisions involving maternal autonomy, fetal viability, religious/cultural values, and outcome data
— Non-directive counseling; document risk/benefit discussion thoroughly
— Some states/jurisdictions have gestational age restrictions on termination — verify legal context; provide referral if institution does not offer
— In monochorionic pregnancies, technique (RFA, cord occlusion) and risk to co-twin must be specifically addressed
— Document discussion of vaginal vs cesarean, including the ~4% risk of combined vaginal–cesarean delivery (Twin A vaginal, Twin B emergent cesarean)
— Ensure availability of experienced operator; safety event if attempted without
— Shared decision-making with neonatology regarding resuscitation, antenatal steroids, magnesium, mode of delivery
— Document parental preferences; revisit as gestation advances
— Pre-conception counseling on single embryo transfer (SET) to reduce iatrogenic multiples
— ASRM guidelines on transfer numbers by age and prognosis
— Maternal transport for fetal therapy: ensure SBAR handoff, transfer of imaging, MFM communication
— Postpartum discharge: explicit return precautions (headache, BP cuff use at home for preeclampsia, fevers, heavy bleeding); follow-up appointment scheduled before discharge
— NICU/maternal separation — psychosocial support and clear communication
— Suspected intimate partner violence (heightened in pregnancy); domestic violence screening at intake and each trimester
— Substance use in pregnancy: state-specific reporting requirements; engage SUD treatment
— When counseling on TTTS laser outcomes, frame in absolute risk and number needed to treat, not just relative risk; many patients misinterpret RR data
Step 3 management: Postpartum twin patient discharged on labetalol after preeclampsia → provide home BP cuff, written threshold for calling (≥160/110 or symptomatic ≥150/100), schedule visit in 3–7 days, document teach-back of warning signs — failure to arrange this is a sentinel safety event.
Board pearl: Postpartum readmissions for preeclampsia peak at 3–10 days — anticipatory discharge planning is the highest-yield safety intervention.
Board pearl: Memorize delivery timing by chorionicity — it is the single most testable management decision in twin pregnancy.
— 8-week pregnancy with size>dates, US shows two gestational sacs each with own yolk sac, thick membrane between, two placentas → DCDA, plan growth scans q4 weeks, ASA, deliver 38 weeks
— MCDA at 22 weeks, US shows one sac with DVP 9 cm and other with DVP 1.5 cm → TTTS Quintero stage I, refer to fetal therapy center, fetoscopic laser for stage II+
— Uncomplicated MCDA at 36 weeks, normal growth, NSTs reactive → deliver 36 0/7–37 6/7 weeks, NOT wait to 39
— Twin A breech, Twin B vertex, 38 weeks → cesarean delivery
— Twin A vertex, Twin B breech, EFW 2400 g/2600 g → vaginal trial with breech extraction of Twin B
— 28-year-old G1 with DCDA at 11 weeks, no other risk factors → ASA 81 mg starting 12–16 weeks
— Twin vaginal delivery, boggy uterus, bleeding → fundal massage, oxytocin already running, methylergonovine (if normotensive) or carboprost (if not asthmatic), TXA, bimanual compression
— MCMA at 28 weeks, no complications → inpatient surveillance, ACS, plan cesarean 32–34 weeks
— Twin delivery 5 days ago, severe headache, BP 168/108 → labetalol IV, magnesium, admit, evaluate for posterior reversible encephalopathy syndrome if neuro signs
— MCDA at 27 weeks, one twin demised → MRI of survivor at 4–6 weeks, expectant management, ACS, NOT emergent delivery
— Twin pregnancy with "no-call" cfDNA → counsel on reduced accuracy in twins, offer diagnostic CVS/amnio for definitive testing
— Vaginal progesterone reasonable; routine cerclage NOT recommended absent history-indicated criteria
— Day 4 postpartum with worsening thrombocytopenia, schistocytes, AKI, neuro changes → TTP, not HELLP → plasma exchange
Board pearl: When a question asks "next best step," default to chorionicity-based surveillance cadence and delivery timing — these are the most commonly tested management points.
In multiple gestation, chorionicity determined by first-trimester ultrasound is the single most important variable, driving surveillance frequency, fetal complications screened for (TTTS/TAPS/sIUGR), delivery timing (DCDA 38, MCDA 36–37 6/7, MCMA 32–34 weeks), mode of delivery (cesarean for non-vertex Twin A or MCMA), and need for fetal therapy referral.
Board pearl: If you can recite the delivery timing by chorionicity, mode of delivery rules, TTTS surveillance interval, and the ASA prophylaxis indication, you have captured 80% of high-yield Step 3 testable content on multiple gestation management. The remainder is procedure-level detail (laser, cord occlusion) and integrated postpartum care — handled like any high-risk obstetric patient with longitudinal follow-up, contraception planning, glycemic re-screening if GDM, and mental health screening for the unique burden of caring for newborn multiples.